CoChat
Sign Up
Cited by 177

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Rac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors

Nieborowska-Skorska, Margaret, Kopinski, Piotr K., Ray, Regina, Hoser, Grazyna, Ngaba, Danielle, Flis, Sylwia, Cramer, Kimberly, Reddy, Mamatha M., Koptyra, Mateusz, Penserga, Tyrone, Glodkowska-Mrowka, Eliza, Bolton, Elisabeth, Holyoake, Tessa L., Eaves, Connie J., Cerny-Reiterer, Sabine, Valent, Peter, Hochhaus, Andreas, Hughes, Timothy P., van der Kuip, Heiko, Sattler, Martin, Wiktor-Jedrzejczak, Wieslaw, Richardson, Christine, Dorrance, Adrienne, Stoklosa, Tomasz, Williams, David A., Skorski, Tomasz·2012·Blood
DOI 10.1182/blood-2011-10-385658
Open this paper in CoChat — free account

Abstract

Chronic myeloid leukemia in chronic phase (CML-CP) is induced by BCR-ABL1 oncogenic tyrosine kinase. Tyrosine kinase inhibitors eliminate the bulk of CML-CP cells, but fail to eradicate leukemia stem cells (LSCs) and leukemia progenitor cells (LPCs) displaying innate and acquired resistance, respectively. These cells may accumulate genomic instability, leading to disease relapse and/or malignant progression to a fatal blast phase. In the present study, we show that Rac2 GTPase alters mitochondrial membrane potential and electron flow through the mitochondrial respiratory chain complex III (MRC-cIII), thereby generating high levels of reactive oxygen species (ROS) in CML-CP LSCs and primitive LPCs. MRC-cIII–generated ROS promote oxidative DNA damage to trigger genomic instability, resulting in an accumulation of chromosomal aberrations and tyrosine kinase inhibitor–resistant BCR-ABL1 mutants. JAK2(V617F) and FLT3(ITD)–positive polycythemia vera cells and acute myeloid leukemia cells also produce ROS via MRC-cIII. In the present study, inhibition of Rac2 by genetic deletion or a small-molecule inhibitor and down-regulation of mitochondrial ROS by disruption of MRC-cIII, expression of mitochondria-targeted catalase, or addition of ROS-scavenging mitochondria-targeted peptide aptamer reduced genomic instability. We postulate that the Rac2-MRC-cIII pathway triggers ROS-mediated genomic instability in LSCs and primitive LPCs, which could be targeted to prevent the relapse and malignant progression of CML.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2011-10-385658

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 40

  1. Hanahan, 2011, Hallmarks of cancer: the next generation., Cell, 144, 646, 10.1016/j.cell.2011.02.013 · DOI · Paper page
  2. Melo, 2007, Chronic myeloid leukaemia as a model of disease evolution in human cancer., Nat Rev Cancer, 7, 441, 10.1038/nrc2147 · DOI
  3. Perrotti, 2010, Chronic myeloid leukemia: mechanisms of blastic transformation., J Clin Invest, 120, 2254, 10.1172/JCI41246 · DOI
  4. Slupphaug, 2003, The interacting pathways for prevention and repair of oxidative DNA damage., Mutat Res, 531, 231, 10.1016/j.mrfmmm.2003.06.002 · DOI
  5. Sallmyr, 2008, Internal tandem duplication of FLT3 (FLT3/ITD) induces increased ROS production, DNA damage, and misrepair: implications for poor prognosis in AML., Blood, 111, 3173, 10.1182/blood-2007-05-092510 · DOI
  6. Koptyra, 2006, BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance., Blood, 108, 319, 10.1182/blood-2005-07-2815 · DOI
  7. Nowicki, 2004, BCR/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species-dependent DNA double-strand breaks., Blood, 104, 3746, 10.1182/blood-2004-05-1941 · DOI
  8. Walz, 2006, Activated Jak2 with the V617F point mutation promotes G1/S phase transition., J Biol Chem, 281, 18177, 10.1074/jbc.M600064200 · DOI
  9. Acín-Pérez, 2004, Respiratory complex III is required to maintain complex I in mammalian mitochondria., Mol Cell, 13, 805, 10.1016/S1097-2765(04)00124-8 · DOI
  10. Wang, 2008, Superoxide flashes in single mitochondria., Cell, 134, 279, 10.1016/j.cell.2008.06.017 · DOI · Paper page
  11. Skorski, 1998, BCR/ABL-mediated leukemogenesis requires the activity of the small GTP-binding protein Rac., Proc Natl Acad Sci U S A, 95, 11858, 10.1073/pnas.95.20.11858 · DOI · Paper page
  12. Hitosugi, 2009, Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth., Sci Signal, 2, ra73, 10.1126/scisignal.2000431 · DOI · Paper page
  13. Koptyra, 2008, BCR/ABL promotes accumulation of chromosomal aberrations induced by oxidative and genotoxic stress., Leukemia, 22, 1969, 10.1038/leu.2008.78 · DOI
  14. King, 1989, Human cells lacking mtDNA: repopulation with exogenous mitochondria by complementation., Science, 246, 500, 10.1126/science.2814477 · DOI
  15. Han, 2008, Early mitochondrial dysfunction in electron transfer activity and reactive oxygen species generation after cardiac arrest., Crit Care Med, 36, S447, 10.1097/CCM.0b013e31818a8a51 · DOI
  16. Wolff, 2001, Establishment of a murine model for therapy-treated chronic myelogenous leukemia using the tyrosine kinase inhibitor STI571., Blood, 98, 2808, 10.1182/blood.V98.9.2808 · DOI
  17. Slupianek, 2011, BCR/ABL stimulates WRN to promote survival and genomic instability., Cancer Res, 71, 842, 10.1158/0008-5472.CAN-10-1066 · DOI
  18. Capizzi, 1973, A table for the estimation of the spontaneous mutation rate of cells in culture., Mutat Res, 17, 147, 10.1016/0027-5107(73)90265-0 · DOI
  19. Sloma, 2010, Insights into the stem cells of chronic myeloid leukemia., Leukemia, 24, 1823, 10.1038/leu.2010.159 · DOI
  20. Valko, 2006, Free radicals, metals and antioxidants in oxidative stress-induced cancer., Chem Biol Interact, 160, 1, 10.1016/j.cbi.2005.12.009 · DOI · Paper page
  21. Smiley, 1991, Intracellular heterogeneity in mitochondrial membrane potentials revealed by a J-aggregate-forming lipophilic cation JC-1., Proc Natl Acad Sci U S A, 88, 3671, 10.1073/pnas.88.9.3671 · DOI
  22. Smith, 2003, Using mitochondria-targeted molecules to study mitochondrial radical production and its consequences., Biochem Soc Trans, 31, 1295, 10.1042/bst0311295 · DOI
  23. Gonzalez, 2007, Chemoreception in the context of the general biology of ROS., Respir Physiol Neurobiol, 157, 30, 10.1016/j.resp.2007.01.016 · DOI
  24. Werner, 2002, Integrins engage mitochondrial function for signal transduction by a mechanism dependent on Rho GTPases., J Cell Biol, 158, 357, 10.1083/jcb.200111028 · DOI
  25. Gao, 2004, Rational design and characterization of a Rac GTPase-specific small molecule inhibitor., Proc Natl Acad Sci U S A, 101, 7618, 10.1073/pnas.0307512101 · DOI · Paper page
  26. Schriner, 2005, Extension of murine life span by overexpression of catalase targeted to mitochondria., Science, 308, 1909, 10.1126/science.1106653 · DOI · Paper page
  27. Sorel, 2004, Evidence of ABL-kinase domain mutations in highly purified primitive stem cell populations of patients with chronic myelogenous leukemia., Biochem Biophys Res Commun, 323, 728, 10.1016/j.bbrc.2004.08.169 · DOI
  28. Skorski, 2002, Oncogenic tyrosine kinases and the DNA-damage response., Nat Rev Cancer, 2, 351, 10.1038/nrc799 · DOI
  29. Naka, 2010, TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia., Nature, 463, 676, 10.1038/nature08734 · DOI
  30. Kang, 1998, Mammalian peroxiredoxin isoforms can reduce hydrogen peroxide generated in response to growth factors and tumor necrosis factor-alpha., J Biol Chem, 273, 6297, 10.1074/jbc.273.11.6297 · DOI
  31. Samudio, 2008, Inhibition of mitochondrial metabolism by methyl-2-cyano-3,12-dioxooleana-1,9-diene-28-oate induces apoptotic or autophagic cell death in chronic myeloid leukemia cells., Mol Cancer Ther, 7, 1130, 10.1158/1535-7163.MCT-07-0553 · DOI
  32. Barnes, 2005, Chronic myeloid leukaemia: an investigation into the role of Bcr-Abl-induced abnormalities in glucose transport regulation., Oncogene, 24, 3257, 10.1038/sj.onc.1208461 · DOI
  33. Amarante-Mendes, 1998, Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome C and activation of caspase-3., Blood, 91, 1700, 10.1182/blood.V91.5.1700 · DOI
  34. Kluza, 2011, Exploiting mitochondrial dysfunction for effective elimination of imatinib-resistant leukemic cells., PLoS One, 6, e21924, 10.1371/journal.pone.0021924 · DOI
  35. Kim, 2005, Activation of the PI3K/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species., Blood, 105, 1717, 10.1182/blood-2004-03-0849 · DOI
  36. Welch, 2003, Phosphoinositide 3-kinase-dependent activation of Rac., FEBS Lett, 546, 93, 10.1016/S0014-5793(03)00454-X · DOI
  37. Harnois, 2003, Differential interaction and activation of Rho family GTPases by p210bcr-abl and p190bcr-abl., Oncogene, 22, 6445, 10.1038/sj.onc.1206626 · DOI · Paper page
  38. Konig, 2008, Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells., Cancer Res, 68, 9624, 10.1158/0008-5472.CAN-08-1131 · DOI
  39. Jiang, 2007, Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells., J Natl Cancer Inst, 99, 680, 10.1093/jnci/djk150 · DOI
  40. Haferlach, 2010, Similar patterns of chromosome abnormalities in CML occur in addition to the Philadelphia chromosome with or without tyrosine kinase inhibitor treatment., Leukemia, 24, 638, 10.1038/leu.2009.222 · DOI

Cited by

See all 177

Metadata

Authors
Nieborowska-Skorska, M., Kopinski, P. K., Ray, R., Hoser, G., Ngaba, D., Flis, S., Cramer, K., Reddy, M. M., Koptyra, M., Penserga, T., Glodkowska-Mrowka, E., Bolton, E., Holyoake, T. L., Eaves, C. J., Cerny-Reiterer, S., Valent, P., Hochhaus, A., Hughes, T. P., van der Kuip, H., Sattler, M., Wiktor-Jedrzejczak, W., Richardson, C., Dorrance, A., Stoklosa, T., Williams, D. A., & Skorski, T.
Affiliations
  • Department of Microbiology and Immunology, Temple University School of Medicine, Philadelphia, PA;
  • Department of Clinical Cytology, Medical Center for Postgraduate Education, Warsaw, Poland;
  • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;
  • Department of Immunology, Medical University of Warsaw, Warsaw, Poland;
  • Paul O'Gorman Leukemia Research Centre, University of Glasgow, Glasgow, United Kingdom;
  • Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, BC;
  • Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna and Ludwig-Boltzmann Oncology Cluster, Vienna, Austria;
  • Department of Hematology/Oncology, Jena University Hospital, Jena, Germany;
  • Department of Hematology and Centre for Cancer Biology, University of Adelaide School of Medicine, Adelaide, Australia;
  • Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology and University of Tuebingen, Stuttgart, Germany;
  • Department of Hematology, Oncology and Internal Diseases, Medical University of Warsaw, Warsaw, Poland;
  • Department of Biology and Center of Bioinformatics, University of North Carolina at Charlotte, Charlotte, NC; and
  • Division of Hematology/Oncology, Children's Hospital Boston, Dana-Farber Cancer Institute, Harvard Medical School, Harvard Stem Cell Institute, Boston, MA
Venue
Blood
Publisher
American Society of Hematology
Published
2012-05-03
Volume
119
Issue
18
Pages
4253-4263
ISSN
  • 0006-4971
  • 1528-0020
DOI
10.1182/blood-2011-10-385658
Cited by
177
References
10
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review